KDR and neoplasm: Axitinib, an inhibitor of the receptor tyrosine kinase (including VEGF receptor [VEGFR] 1-3) [30], inhibits the VEGF/VEGFR signaling, disrupting its blood supply, and causing tumor cells to “starve”, thus exerting antitumor activity.